$SLRX
Salarius Pharmaceuticals, Inc.

2019 Q2 Form 10-Q Financial Statement

#000161521919000020 Filed on May 01, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q1
Revenue $895.8K $105.0K $178.6K
YoY Change 264.88% -41.22% -26.37%
Cost Of Revenue $36.15K $47.33K $83.93K
YoY Change -79.91% -43.61% 6.1%
Gross Profit $859.6K $57.65K $94.65K
YoY Change 1211.27% -39.09% -42.09%
Gross Profit Margin 95.96% 54.91% 53.0%
Selling, General & Admin $970.0K $1.490M $3.700M
YoY Change -65.11% -59.73% -19.39%
% of Gross Profit 112.84% 2584.65% 3909.22%
Research & Development $840.1K $1.706K $4.680M
YoY Change -86.39% -99.96% 19.55%
% of Gross Profit 97.73% 2.96% 4944.83%
Depreciation & Amortization $10.00K $36.45K $64.07K
YoY Change -83.33% -43.1% -29.88%
% of Gross Profit 1.16% 63.23% 67.69%
Operating Expenses $1.808M $2.349M $8.461M
YoY Change -80.66% -72.24% -1.48%
Operating Profit -$912.1K -$2.244M -$8.283M
YoY Change -89.98% -72.91% -0.76%
Interest Expense $8.457K $0.00 $60.00K
YoY Change -83.09% -100.0% -25.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $10.00K
YoY Change
Pretax Income -$900.0K -$1.520M -$8.220M
YoY Change -90.06% -81.51% -0.6%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$903.6K -$1.522M -$381.5K
YoY Change -912.39% 298.92% -95.39%
Net Earnings / Revenue -100.88% -1449.91% -213.65%
Basic Earnings Per Share
Diluted Earnings Per Share -$298.0K -$641.4K -$11.42M
COMMON SHARES
Basic Shares Outstanding 18.07M shares 18.07M shares 17.97M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.500M $7.300M $23.90M
YoY Change -58.86% -69.46% -54.73%
Cash & Equivalents $6.514M $7.297M $22.07M
Short-Term Investments $2.000M
Other Short-Term Assets $400.0K $700.0K $1.300M
YoY Change -55.56% -46.15% -18.75%
Inventory $130.9K $164.6K $418.2K
Prepaid Expenses
Receivables $28.28K $9.069K $12.63K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.109M $8.146M $25.64M
YoY Change -57.95% -68.23% -53.24%
LONG-TERM ASSETS
Property, Plant & Equipment $27.95K $38.01K $266.6K
YoY Change -84.47% -85.75% -44.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K
YoY Change 54.32%
Total Long-Term Assets $27.95K $38.01K $393.2K
YoY Change -90.88% -90.33% -41.37%
TOTAL ASSETS
Total Short-Term Assets $7.109M $8.146M $25.64M
Total Long-Term Assets $27.95K $38.01K $393.2K
Total Assets $7.137M $8.184M $26.03M
YoY Change -58.53% -68.56% -53.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $805.5K $186.3K $2.241M
YoY Change -29.67% -91.69% 173.74%
Accrued Expenses $200.0K $700.0K $1.800M
YoY Change -92.31% -61.11% -21.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.036M $911.1K $4.121M
YoY Change -72.68% -77.89% 28.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.036M $911.1K $4.121M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.036M $911.1K $4.145M
YoY Change -72.75% -78.02% 26.47%
SHAREHOLDERS EQUITY
Retained Earnings -$136.6M -$135.2M -$119.3M
YoY Change 6.44% 13.36% 40.45%
Common Stock $1.807K $1.807K $1.798K
YoY Change 0.0% 0.5% 5.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $732.9K $1.730M -$3.316M
YoY Change
Total Liabilities & Shareholders Equity $7.137M $8.184M $26.03M
YoY Change -58.53% -68.56% -53.1%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$903.6K -$1.522M -$381.5K
YoY Change -912.39% 298.92% -95.39%
Depreciation, Depletion And Amortization $10.00K $36.45K $64.07K
YoY Change -83.33% -43.1% -29.88%
Cash From Operating Activities -$1.530M -$2.659M -$9.412M
YoY Change -81.48% -71.75% 14.43%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $12.12M
YoY Change 75.65%
Cash From Investing Activities $0.00 $12.12M
YoY Change -100.0% 76.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -100.0K $0.00 $54.91K
YoY Change -242.86% -100.0%
NET CHANGE
Cash From Operating Activities -1.530M -$2.659M -$9.412M
Cash From Investing Activities $0.00 $12.12M
Cash From Financing Activities -100.0K $0.00 $54.91K
Net Change In Cash -1.630M -$2.659M $2.762M
YoY Change -73.67% -196.25% -305.48%
FREE CASH FLOW
Cash From Operating Activities -$1.530M -$2.659M -$9.412M
Capital Expenditures $0.00
Free Cash Flow -$9.412M
YoY Change 14.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001615219
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18069476 shares
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
Flex Pharma, Inc.
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
764340 USD
CY2019Q1 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
724769 USD
CY2018Q4 flks Accrued Research And Development Expense Other Current
AccruedResearchAndDevelopmentExpenseOtherCurrent
2846 USD
CY2019Q1 flks Accrued Research And Development Expense Other Current
AccruedResearchAndDevelopmentExpenseOtherCurrent
0 USD
CY2019Q1 flks Common Stock Numberof Votes
CommonStockNumberofVotes
1 vote
flks Contractwith Customer Refund Period
ContractwithCustomerRefundPeriod
P30D
flks Contractwith Customer Refund Period
ContractwithCustomerRefundPeriod
P14D
flks Numberof Retained Employees
NumberofRetainedEmployees
7 employee
CY2019Q1 flks Percentage Decreasein Company Workforce
PercentageDecreaseinCompanyWorkforce
0.60
CY2018Q1 flks Sales Discounts
SalesDiscounts
8000 USD
CY2019Q1 flks Sales Discounts
SalesDiscounts
1000 USD
CY2018Q2 flks Sharebased Compensation Arrangementby Sharebased Payment Award Numberof Employees Granted Options
SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofEmployeesGrantedOptions
7 employee
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
342530 USD
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
186349 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9939 USD
CY2019Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9069 USD
CY2018Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
5360 USD
CY2019Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
7170 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
269544 USD
CY2019Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
681360 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
142242224 USD
CY2019Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
142463199 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
908940 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
220975 USD
CY2018Q1 us-gaap Advertising Expense
AdvertisingExpense
508000 USD
CY2019Q1 us-gaap Advertising Expense
AdvertisingExpense
10000 USD
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
908940 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
220975 USD
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3132478 shares
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2298495 shares
CY2018Q4 us-gaap Assets
Assets
10389626 USD
CY2019Q1 us-gaap Assets
Assets
8184419 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
10315166 USD
CY2019Q1 us-gaap Assets Current
AssetsCurrent
8146411 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0 USD
CY2019Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9829624 USD
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7297468 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19312631 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22074990 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9956219 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7297468 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2658751 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2762359 USD
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18069476 shares
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18069476 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18067392 shares
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18068017 shares
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1807 USD
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
1807 USD
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8221887 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2230430 USD
CY2018Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
83934 USD
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
47329 USD
CY2018Q1 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
40217 USD
CY2018Q1 us-gaap Depreciation
Depreciation
64066 USD
CY2019Q1 us-gaap Depreciation
Depreciation
36452 USD
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
417997 USD
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
36239 USD
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M15D
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1938000 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3697287 USD
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2299585 USD
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
236962 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-156181 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4514 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-870 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1895468 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-39571 USD
CY2018Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-14705 USD
CY2019Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
0 USD
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3297 USD
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-22323 USD
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
499023 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
513189 USD
CY2018Q1 us-gaap Interest Income Operating
InterestIncomeOperating
59593 USD
CY2019Q1 us-gaap Interest Income Operating
InterestIncomeOperating
13213 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
186920 USD
CY2019Q1 us-gaap Inventory Net
InventoryNet
164597 USD
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7247 USD
CY2019Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7247 USD
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
179673 USD
CY2019Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
157350 USD
CY2018Q1 us-gaap Inventory Write Down
InventoryWriteDown
0 USD
CY2019Q1 us-gaap Inventory Write Down
InventoryWriteDown
0 USD
CY2018Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-12231 USD
CY2019Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
0 USD
CY2018Q4 us-gaap Liabilities
Liabilities
1106870 USD
CY2019Q1 us-gaap Liabilities
Liabilities
911118 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10389626 USD
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8184419 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1106870 USD
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
911118 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54913 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12119933 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9412487 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2658751 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-8223227 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2230430 USD
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8223227 USD
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2230430 USD
CY2019Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
8461402 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
2348620 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8282820 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2243643 USD
CY2018Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1340 USD
CY2019Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2018Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3480 USD
CY2019Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2019Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
57365 USD
CY2018Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1997751 USD
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
162088 USD
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
675277 USD
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
14117184 USD
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
CY2018Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
500 USD
CY2019Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
54913 USD
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74460 USD
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38008 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4680181 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1706 USD
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
126595 USD
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0 USD
us-gaap Restructuring Charges
RestructuringCharges
1765000 USD
CY2019Q1 us-gaap Restructuring Charges
RestructuringCharges
-11000 USD
CY2018Q4 us-gaap Restructuring Reserve
RestructuringReserve
68593 USD
CY2019Q1 us-gaap Restructuring Reserve
RestructuringReserve
0 USD
CY2018Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
68593 USD
CY2019Q1 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
0 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132961275 USD
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135191705 USD
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
178582 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
104977 USD
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
908940 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
220975 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P48M
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1237034 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.31
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
23945 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
654544 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2320981 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2297036 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.10
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.10
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2297036 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.10
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.00
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4.41
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.00
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.00
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M2D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M10D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M10D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y4M10D
CY2019Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2018Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
54913 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
29105888 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
21888071 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
9282756 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
7273301 USD
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17893912 shares
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18067807 shares
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates, which include, but are not limited to, estimates related to clinical study accruals, estimates related to inventory realizability, stock-based compensation expense and amounts of expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001615219-19-000020-index-headers.html Edgar Link pending
0001615219-19-000020-index.html Edgar Link pending
0001615219-19-000020.txt Edgar Link pending
0001615219-19-000020-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
flks-20190331.xml Edgar Link completed
flks-20190331.xsd Edgar Link pending
flks-20190331_cal.xml Edgar Link unprocessable
flks-20190331_def.xml Edgar Link unprocessable
flks-20190331_lab.xml Edgar Link unprocessable
flks-20190331_pre.xml Edgar Link unprocessable
flks2019033110-q.htm Edgar Link pending
flks20190331ex-311.htm Edgar Link pending
flks20190331ex-312.htm Edgar Link pending
flks20190331ex-321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending